S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
Log in
NASDAQ:TWST

Twist Bioscience Stock Forecast, Price & News

$205.49
+24.14 (+13.31 %)
(As of 01/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$185.00
Now: $205.49
$207.12
50-Day Range
$111.74
MA: $150.37
$189.43
52-Week Range
$18.52
Now: $205.49
$207.12
Volume1.05 million shs
Average Volume775,621 shs
Market Capitalization$9.99 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.83
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.

MarketRank

Overall MarketRank

1.23 out of 5 stars

Analyst Opinion: 1.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TWST
CUSIPN/A
CIKN/A
Phone800-719-0671
Employees525

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$90.10 million
Book Value$7.53 per share

Profitability

Net Income$-139,930,000.00
Net Margins-155.31%

Miscellaneous

Market Cap$9.99 billion
Next Earnings Date2/4/2021 (Estimated)
OptionableNot Optionable
$205.49
+24.14 (+13.31 %)
(As of 01/19/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TWST News and Ratings via Email

Sign-up to receive the latest news and ratings for TWST and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Twist Bioscience (NASDAQ:TWST) Frequently Asked Questions

How has Twist Bioscience's stock been impacted by Coronavirus?

Twist Bioscience's stock was trading at $28.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TWST shares have increased by 628.7% and is now trading at $205.49.
View which stocks have been most impacted by COVID-19
.

Is Twist Bioscience a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Twist Bioscience stock.
View analyst ratings for Twist Bioscience
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Twist Bioscience?

Wall Street analysts have given Twist Bioscience a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Twist Bioscience wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Twist Bioscience's next earnings date?

Twist Bioscience is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Twist Bioscience
.

How were Twist Bioscience's earnings last quarter?

Twist Bioscience Co. (NASDAQ:TWST) released its quarterly earnings data on Sunday, November, 22nd. The company reported ($0.54) earnings per share for the quarter, beating analysts' consensus estimates of ($0.70) by $0.16. The company earned $32.43 million during the quarter, compared to analyst estimates of $22.70 million. Twist Bioscience had a negative net margin of 155.31% and a negative return on equity of 44.62%.
View Twist Bioscience's earnings history
.

What guidance has Twist Bioscience issued on next quarter's earnings?

Twist Bioscience issued an update on its FY 2021 Pre-Market earnings guidance on Monday, November, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $110-118 million, compared to the consensus revenue estimate of $117.94 million.

What price target have analysts set for TWST?

4 equities research analysts have issued 1 year price objectives for Twist Bioscience's shares. Their forecasts range from $42.00 to $125.00. On average, they anticipate Twist Bioscience's share price to reach $89.00 in the next year. This suggests that the stock has a possible downside of 56.7%.
View analysts' price targets for Twist Bioscience
or view Wall Street analyst' top-rated stocks.

Are investors shorting Twist Bioscience?

Twist Bioscience saw a drop in short interest during the month of December. As of December 31st, there was short interest totaling 2,920,000 shares, a drop of 20.0% from the December 15th total of 3,650,000 shares. Based on an average trading volume of 643,800 shares, the short-interest ratio is currently 4.5 days.
View Twist Bioscience's Short Interest
.

Who are some of Twist Bioscience's key competitors?

What other stocks do shareholders of Twist Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD), Pfizer (PFE), DocuSign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), JD.com (JD), Tesla (TSLA) and Twilio (TWLO).

Who are Twist Bioscience's key executives?

Twist Bioscience's management team includes the following people:
  • Dr. Emily Marine Leproust, Co-Founder, Chairman, Pres & CEO (Age 47, Pay $935.79k)
  • Mr. James M. Thorburn, Chief Financial Officer (Age 65, Pay $597.2k)
  • Dr. Patrick John Finn, Chief Commercial Officer (Age 49, Pay $558.68k)
  • Mr. Patrick Weiss, Chief Operating Officer (Age 50)
  • Mr. Mark Daniels Esq., Sr. VP, Chief Legal Officer, Chief Ethics & Compliance Officer and Sec. (Age 58)
  • Ms. Paula Green, VP of HR (Age 53)
  • Dr. William Charles Banyai, Sr. VP of Advanced Devel., GM of Data Storage & Director (Age 66)
  • Dr. Aaron K. Sato, Chief Scientific Officer of BioPharma & VP of Protein Engineering
  • Mr. Martin Kunz, Sr. VP of Operations (Age 50)
  • Ms. Erin Smith, Sr. VP of Gov. Affairs & Public Policy

When did Twist Bioscience IPO?

(TWST) raised $75 million in an IPO on Wednesday, October 31st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Cowen served as the underwriters for the IPO and Allen & Company and Baird were co-managers.

What is Twist Bioscience's stock symbol?

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

How do I buy shares of Twist Bioscience?

Shares of TWST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Twist Bioscience's stock price today?

One share of TWST stock can currently be purchased for approximately $205.49.

How big of a company is Twist Bioscience?

Twist Bioscience has a market capitalization of $9.99 billion and generates $90.10 million in revenue each year. The company earns $-139,930,000.00 in net income (profit) each year or ($3.00) on an earnings per share basis. Twist Bioscience employs 525 workers across the globe.

What is Twist Bioscience's official website?

The official website for Twist Bioscience is www.twistbioscience.com.

How can I contact Twist Bioscience?

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 800-719-0671 or via email at [email protected]

This page was last updated on 1/20/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.